Keyphrases
Acute Myeloid Leukemia
100%
In Cancer
100%
Cancer Immunotherapy
100%
Regulatory T Cells
100%
Molecular Markers
100%
Regulatory T (Treg) Cells
57%
CD25
57%
Forkhead Box P3 (FOXP3)
42%
Leukemia Therapy
42%
Tumor Microenvironment
28%
Adverse Effects
28%
Treg
28%
Cancer Genome Atlas
28%
Recent Advances
14%
Therapeutic Strategies
14%
Patient Survival
14%
Tyrosine Kinase Receptor
14%
Clinical Efficacy
14%
Tumor Immunity
14%
Adverse Reactions
14%
Phosphoinositide 3-kinase (PI3K)
14%
Novel Therapies
14%
Interleukin-2
14%
Treatment Strategy
14%
Common Cancers
14%
Prostate Carcinoma
14%
Programmed Death-ligand 1 (PD-L1)
14%
Future Therapies
14%
Risk Effects
14%
PD-1 Inhibitor
14%
Tumor Treatment
14%
Anti-CD25
14%
Immune Disorders
14%
Treg Therapy
14%
Lung Adenocarcinoma
14%
Cytotoxic T-lymphocyte antigen-4 (CTLA-4)
14%
Anti-CTLA-4
14%
Treg Markers
14%
Foxp3+ Tregs
14%
Prognosticate
14%
Medicine and Dentistry
Systematic Review
100%
Regulatory T Cell
100%
Cancer Immunotherapy
100%
Molecular Marker
100%
Acute Myeloid Leukemia
100%
Immunotherapy
71%
Malignant Neoplasm
57%
Cancer
42%
Tumor Microenvironment
28%
Adverse Effect
28%
CTLA-4
28%
Cancer Treatment
14%
Adverse Event
14%
Interleukin 2
14%
Tyrosine Kinase Receptor
14%
Lung Adenocarcinoma
14%
Immune Disorder
14%
Prostate Adenocarcinoma
14%
Cell Therapy
14%
Immunology and Microbiology
Myeloid
100%
Regulatory T Cell
100%
Cancer Immunotherapy
100%
Genetic Marker
100%
CD25
62%
Immunotherapy
62%
CTLA-4
25%
Interleukin 2
12%
Tyrosine
12%
Immune System Disorders
12%
Pharmacology, Toxicology and Pharmaceutical Science
Malignant Neoplasm
100%
Immunotherapy
100%
Molecular Marker
100%
Acute Myeloid Leukemia
100%
Tumor Microenvironment
28%
Cytotoxic T Lymphocyte Antigen 4
28%
Neoplasm
14%
Adverse Event
14%
Interleukin 2
14%
Prostate Adenocarcinoma
14%
Lung Adenocarcinoma
14%
Tyrosine Kinase Receptor
14%